Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives $37.71 Consensus Price Target from Brokerages

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. […]

Related Keywords

China ,Jennifer Kayden Lee ,Hunterc Smith ,Needham Company ,Rhythm Pharmaceuticals Stock Down ,Ameritas Investment Partners Inc ,Securities Exchange Commission ,Institutional Trading Of Rhythm Pharmaceuticals ,Allspring Global Investments Holdings ,Wells Fargo Company ,News Ratings For Rhythm Pharmaceuticals Daily ,Analyst Recommendations For Rhythm Pharmaceuticals ,Goldman Sachs Group ,Rhythm Pharmaceuticals Inc ,Morgan Stanley ,Nasdaq ,Life Insurance Co ,China Universal Asset Management Co ,Rhythm Pharmaceuticals ,Get Free Report ,Marketbeat Ratings ,Wells Fargo ,Exchange Commission ,Kayden Lee ,Universal Asset Management ,Global Investments Holdings ,Ameritas Investment Partners ,Pharmaceuticals Stock Down ,Get Free ,Rhythm Pharmaceuticals Daily ,Nasdaq Rytm ,Rytm ,Medical ,Ratings ,Consensus ,